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Objectives: Zoledronic acid (ZA) reduces the risk of skeletal-related 
events (SREs) in lung cancer patients with bone metastases. This 
analysis assessed, from the perspective of a French or German payer, 
the economic impact of ZA therapy in patients with bone metastases 
secondary to lung cancer.
Methods: A literature-based model was developed to compare the esti-
mated direct costs and quality adjusted life years (QALY) experienced 
by lung cancer patients with bone metastases receiving placebo or ZA. 
Survival, SRE incidence, and number of infusions administered were 
obtained from a randomized clinical trial comparing patients receiv-
ing 4 mg ZA to patients receiving placebo every three weeks for up to 
21 months. Drug acquisition and administration costs were estimated 
using published sources. The cost of an SRE avoided (€3,567 in both 
countries) was estimated on the basis of an analysis pooling 121 SREs 
among 71 Dutch patients with various cancers reported as three sepa-
rate series by the Institute for Medical Technology Assessment, Eras-
mus MC, University Medical Center Rotterdam, The Netherlands. The 
impact of SREs on quality of life was estimated using the literature. 
Consistent with previous economic analyses of bisphosphonates in can-
cers (e.g., Hillner et al, 2000), patients avoiding SREs were assumed to 
experience quality of life improvements for 1 month.
Results: The remaining life expectancy was conservatively estimated 
to be 8.50 months on average (median, 5.89 months) and was assumed 
to be equal in both groups. During those months of survival, patients 
receiving placebo were projected to experience 2.07 SREs on average 
vs. 1.32 SREs among ZA patients. QALYs were estimated at 0.3523 
per patient (pp) and 0.3350 pp in the ZA and placebo groups, respec-
tively. ZA drug-related costs were estimated at €2,201 in Germany and 
€1,232 pp in France, based on a total of 5.87 infusions pp and a cost 
per infusion of €374.93 in Germany and €210 in France. The use of 
ZA was associated with a reduction of €2,676.72 pp in SRE costs in 
both countries. Overall, therefore, ZA saved €476 pp in Germany and 
€1,444 pp in France. The use of ZA resulted in a net increase of 0.0173 
QALYs pp compared to no therapy. In sensitivity analyses, ZA cost 
€30,000 or less per QALY under a wide range of assumptions.
Conclusions: The use of ZA leads to fewer SREs, better estimated 
quality of life, and lower costs relative to placebo in French and Ger-
man lung cancer patients with bone metastases. The use of ZA in these 
populations therefore appears to provide cost savings and is highly cost 
effective (i.e., cost per QALY saved of €30,000 or less).
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Background: The IRMA study reported the high prevalence of renal 
insufﬁciency (RI) in 4684 cancer patients, with a glomerular ﬁltration 
rate (GFR) <90 ml/min for near 60%. Furthermore, 80.1% were receiv-
ing nephrotoxic drugs and 79.9% drugs necessitating dosage adjust-
ment. We present the results for IRMA patients with lung cancer.
Methods: Among IRMA patients for which type of tumour, sex, age, 
weight, serum creatinine (SCR), haemoglobinemia, and anticancer 
drugs were collected, those with lung cancer underwent subgroup 
analysis (no dialysis, no myeloma). The prevalence of SCR>110 mol/L 
was assessed. GFR was estimated with the Cockcroft-Gault (CG) and 
the abbreviated MDRD (aMDRD) formulae. Patients were classiﬁed 
according to their GFR (Table). Among anticancer drugs prescribed, 
those necessitating dosage adjustment and those potentially nephro-
toxic were identiﬁed.
Results: 445 patients were included: mean age 61.1 years, weight 
65.8 kg, sex-ratio (M/F) 2.37. The prevalence of SCR>110 mol/L was 
14.4%. That of GFR<90 ml/min (or mL/min/1.73m2) was 62.1% with 
CG and 56% with aMDRD. Among patients with normal SCR, 60.1% 
and 51.7% had abnormal CG and aMDRD, respectively. 67.5% of the 
644 prescriptions were drugs needing dosage adjustment (or no data) 
and 80.6% of treated patients received at least one such drug. 71.3% 
of all prescriptions were potentially nephrotoxic and 83.5% of treated 
patients received at least one nephrotoxic drug. 50.1% and 28.8% had a 
serum haemoglobin lower than 12 and 11 g/dL, respectively.
Conclusions: RI is highly frequent in lung cancer patients and SCR 
dramatically underestimates this prevalence. Appropriate evaluation of 
renal function necessitates CG or aMDRD calculation. Nearly all those 
patients were treated with drugs that may necessitate dosage adjustment 
and half of them were receiving potentially nephrotoxic anticancer 
drugs. Furthermore, anemia was still highly frequent.
RI stages in IRMA lung cancer patients:
GFR (mL/min or mL/min/1.73m2) CG aMDRD
>=90 31% 38.9%
60-89 38.7% 38.9%
30-59 21.4% 16.4%
<30 2% 0.7%
Data not available 7% 5.2%
